Teewinot Life Sciences Corporation, an industry leader in discovery, development and commercialization of cannabinoid-based therapeutics and the global leader in the biocatalytic production of cannabinoids, closed its $12.3 million Series B round led by Tuatara Capital, a New York based private equity fund focused on investments in cannabis-related companies.  With the original Series B target having been set at $10 million, the funds raised were nearly 25 percent oversubscribed.  Tuatara Capital also led Teewinot's $7 million Series A round in December 2015.

Teewinot Life Sciences Corporation is an international biopharmaceutical company focused on advanced pharmaceutical research and the use of novel biosynthetic processes such as biocatalysis and synthetic biology for cannabinoid manufacture.  Coupled with patented formulation technologies, Teewinot is a leader in the production and delivery of cannabinoid-based therapies.

Teewinot has introduced new and unique methods of production to the pharmaceutical industry that reduces cost and production time, increases purity of cannabinoids, and diversifies the number and types of molecules which can be made available to the research, product development, and commercial production verticals.